Still, one drug can fit many. Maybe a drug can fit most. Figuring those many indications out is a challenge and the designers of the trial addressed it by not taking on all comers, but by considering just those that have achieved a favorable response to chemotherapy. A simple segregation approach. We'll find out if that specific qualification decision was correct, and soon.
You establish your objections to the trial design, and your indecisiveness over its chances of success on a "all comers" fault. The fault does not exist, certainly not in any meaningful way.
What else drives your skepticism, apart from your admiration of HB?
Market Data 
Markets 
AI
